Introduction
Cytochrome P450 (P450, EC 1.14.14.1) enzymes have been characterized with respect to drug metabolism and disposition (Johansson and Ingelman-Sundberg, 2011) . Research has focused on the P450s as well as on another monooxygenase family, the flavin-containing monooxygenases (FMOs, EC 1.14.13.8) , involved in the oxidation of a variety of compounds associated with pharmacological and/or toxicological effects in humans. The potential pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) degenerates dopaminergic neurons and causes Parkinsonism in primates, including common marmosets, cynomolgus monkeys, and humans (Davis et al., 1997; Langston and Ballard, Jr., 1983; Ballard et al., 1985) . (Chiba et al., 1985) . The metabolic transformation of MPTP to its toxic metabolite MPP + via intermediate MPDP + is mediated by monoamine oxidase or P450 2D6 in human brains (Davis et al., 1997; Langston and Ballard, Jr., 1983; Ballard et al., 1985) . On the other hand, MPTP is also metabolized to non-neurotoxic 4-phenyl-1,2,3,6-tetrahydropyridine (PTP) and MPTP N-oxide ( Fig. 1 ) by P450 2D6 and FMO, respectively, in human livers (Herraiz et al., 2013; Bajpai et al., 2013) .
The common marmoset (Callithrix jacchus) is a member of the New World non-human primate family Callitrichidae (Abbott et al., 2003; Mansfield, 2003; Carrion, Jr. and Patterson, 2012; Okano et al., 2012; Tokuno et al., 2012) . The species has attracted considerable attention as a potentially useful animal model in fields such as neuroscience and drug DMD # 63594 6 toxicology (Mansfield, 2003) because of its size, availability, unique biological characteristics (Abbott et al., 2003) , and evidence of cross-reactivity with human cytokines and hormones (Okano et al., 2012) . In particular, MPTP-treated marmosets have been used for preclinical studies on Parkinson disease (Eslamboli, 2005; Jenner, 2009 ). The parkinsonian marmosets have shown characteristic neural degeneration of nigrostriatal dopamine neurons and behavioral signs such as moving tremors, immobility, muscle rigidity, positional dysfunction, and L-dopa-induced dyskinesia (Ando et al., 2014; Ando et al., 2012) .
However, we do not yet have a comprehensive understanding of common marmoset drug metabolizing enzymes related to MPTP metabolism, partly because of the absence of an available reference genome sequence or enzyme characteristics. Although we recently carried out identification and quantitative analysis of tissue-specific mRNA transcripts of P450s and FMOs in the marmoset as an animal model in drug development , limited numbers of P450 isoforms and no FMOs in the marmoset have been investigated in terms of their drug metabolizing activities so far.
The present study combined analyses to identify novel common marmoset FMO1/3 and P450 enzymes that have until now been unreported and to investigate MPTP oxidative metabolism. We report herein that marmoset FMO3 mainly contributed to deactivation of MPTP and that marmoset P450 2D6 was responsible for both deactivation and metabolic activation of MPTP to MPP + . The present findings should prove an important resource for future biomedical research and will facilitate use of the common marmoset as an animal preclinical Parkinsonism model. 
Materials and Methods

Animals
Adult common marmosets (>2 years old) were purchased from CLEA Japan (Tokyo, Japan common marmosets (five males and six females, 2-6 years of age) after euthanasia by exsanguination under ketamine (60 mg/kg) and isoflurane deep anesthesia as described previously respectively. Microsomal fractions from marmoset tissue samples were prepared as described previously Yamazaki et al., 2002) . Microsomal samples DMD # 63594 8 from a baculovirus-insect cell line (Supersomes) expressing human P450 1A1, 2A6, 2B6,   2C8, 2C9, 2C19, 2D6, 2E1, 3A4 , and 3A5 were purchased from Corning. The other chemicals and reagents used were obtained in the highest grade commercially available.
Molecular cloning of cDNAs for marmoset P450s and FMOs
To obtain cDNAs of marmoset P450s and FMOs, reverse transcription (RT)-polymerase chain reaction (PCR) was performed using brain and liver total RNAs of marmosets. Total RNA was isolated from each tissue using RNeasy Mini Kits (QIAGEN, Valencia, CA) according to the protocols of the manufacturer's instructions, and then a first-strand cDNA was prepared by RT reaction at 50°C for 1 h in a mixture containing 1 μg of total RNA, oligo(dT), and SuperScript III RT reverse transcriptase (Invitrogen, Carlsbad, CA). PCR was performed using KOD-plus-neo DNA polymerase (Toyobo, Osaka, Japan) with RT product as described by the protocols of the manufacturer's instructions. 
Recombinant marmoset P450s and FMOs
Recombinant marmoset P450s (P450 1A2, 2B6, 2C8, 2D6, 2E1, 3A4, 3A5, and 3A90) and FMOs (FMO1 and FMO3) were heterologously expressed in Escherichia coli using expression plasmids. For P450s, the N-terminus modification was conducted by PCR using the forward and reverse primers,
5′-GGAATTCCATATGGCTCTGTTATTAGCAGTTTTTTTCTCAGCCACAGAGCTTCTC
CT-3′ and 5′-GCTCTAGACGGTGTCTTCCTCACTGGAAGG-3′ for P450 1A2, 
5′-GGAATTCCATATGGCTCTGTTATTAGCAGTTTTTTTTGCACTCCTCACAGGCCTTT
5′-GGAATTCCATATGGCTCTGTTATTAGCAGTTTTTGCCCTGCTGATATGGGCGGCC
ATTCTCCTGCT-3′ and 5′-GCTCTAGACGAGTGTGTCCTCCTCACACTGAT-3′ for P450
2E1, 5′-GGAATTCCATATGGCTCTGTTATTAGCAGTTTTTGTGGAAACCTGGCTTCTCCTG-3′ and 5′-GCTCTAGAGGAAATTCAGGCTCCACTTACAGTC-3′ for P450 3A4, and 5′-GGAATTCCATATGGCTCTGTTATTAGCAGTTTTTGTGGAAACCTGGCTTCTCCTG-3′ and 5′-GCTCTAGATCATTCTCCACTTAGGGTTCCATCTC-3′ for P450 3A90, respectively. The NdeI and XbaI sites (underlined) in the forward and reverse primers, respectively, were used for subcloning of the product into pCW vectors that contained human NADPH-P450 reductase cDNA . Membrane preparation and measurement of P450 protein and reductase contents in each sample were performed as described previously . Expected drug oxidation activities of marmoset P450 enzymes were confirmed with typical human P450 probe substrates (Uehara et al., 2011; Yamazaki et al., 2002) . 5′-CCGCTCGAGTTAGGTCAACCCAAGGAAAACAGCAA-3′ for FMO3. After restriction enzyme digestion using XhoI (the restriction site is underlined), the PCR products were subcloned to pET30 vectors (Novagen, Madison, WI) to provide a 6×His-tag at the N-terminus (Uno et al., 2013) . Protein expression and E. coli membrane preparations were performed as described previously in a similar manner to that used for human FMO1 and FMO3 preparations. The final amount of recombinant FMO proteins in bacterial membranes were normalized to the flavin adenine dinucleotide contents . Expected drug oxygenation activities of marmoset FMO1/3 were confirmed with the typical FMO probe substrate benzydamine .
MPTP oxidation catalyzed by marmoset P450s and FMOs
The four metabolites of MPTP, namely PTP, MPTP N-oxide, MPDP + , and MPP + ( Fig. 1 ),
were determined as described previously (Herraiz et al., 2013) with minor modifications.
Briefly, reaction mixtures of 0.25 mL contained enzyme sources (microsomal preparations or E. coli membranes), 100 mM potassium phosphate buffer (pH 7.4), an NADPH-generating system (0.5 mM NADP + , 5 mM glucose 6-phosphate, 5 mM MgCl 2 , and 1 U/ml glucose-6-phosphate dehydrogenase), and 1-2000 μ M MPTP, unless otherwise specified.
After incubation for 10 min at 37°C, the reaction was terminated by the addition of 25 ) were approximately 2-and 4-fold faster, respectively, than PTP formation rates (Fig. 3A) .
The formation rates of four MPTP metabolites in individual marmosets varied less than 5-fold within the liver and brain microsomes analyzed in the present study (Fig. 3) ; larger inter-individual variations in the marmoset were observed for MPP + formation in the brain (4.7-fold). Interestingly, PTP formation rates ( The effects of P450 and FMO inhibitors (α-naphthoflavone, sulfaphenazole, ticlopidine, quinidine, ketoconazole and methimazole) on MPTP oxidation in liver microsomes were investigated at substrate concentrations of 50 μM of MPTP (Fig. 4) . Quinidine (1-10 μM), a P450 2D inhibitor, strongly inhibited MPTP N-demethylation (PTP formation) (Fig. 4A) and moderately suppressed MPP + formation (Fig. 4D ) in marmoset liver microsomes.
Ticlopidine (2-20 μM), a P450 2C inhibitor, moderately suppressed MPTP N-demethylation ( Fig. 4A ) and MPP + formation (Fig. 4D ) in liver microsomes. Marmoset FMO3 (Fig. 2C ) catalyzed MPTP N-oxygenation (14.5 nmol/min/nmol FMO, 
Discussion
Oxidation of potential pro-neurotoxin MPTP has been reported in various animal species, including mouse, rat, and human (Chiba et al., 1990; Coleman et al., 1996; Yoshihara et al., 2000) . In vitro studies using rat liver microsomes have shown approximately 20 times faster MPTP N-oxygenation rates than MPTP N-demethylation rates (Cashman and Ziegler, 1986 ).
In the present study, fast MPTP N-oxygenation reactions in vitro were confirmed in marmoset liver and brain microsomes (Fig. 3) . These facts suggest that MPTP N-oxygenation might be the major detoxification pathway in most animal species, including common marmosets.
MPTP N-oxygenation in marmoset liver microsomes was likely mediated by FMO3 because of suppression of the reaction by methimazole (an inhibitor for FMO, Fig. 4 ) and the high metabolic capacity of marmoset FMO3 compared to FMO1 (Table 3 ). In terms of
FMO-mediated reactions, apparent K m values for NADPH-dependent drug oxygenations
were generally in the range ~50-100 µM , presumably because FMO exhibits a stable 4a-flavin hydroperoxide intermediate capable of oxygenating both nucleophiles and electrophiles in its catalytic cycle, even in the absence of an oxygenatable substrate (Jones and Ballou, 1986) .
In the present study, the main roles of liver microsomal P450 2D6 and FMO3 in MPTP oxidation in common marmosets were demonstrated (Table 3 and were consistent (Table 3) , although minor roles of other P450 isoforms could not be ruled out.
It should be noted that occasional species differences were seen with regard to the roles of P450 enzymes between marmosets and humans (Fig. 5) ; human P450 1A2 seemed to have high capacity for MPDP + and MPP + formation under the present conditions. Although monoamine oxidase exists in another cellar fraction was not tested in the present study, these results collectively suggested that, in the marmoset, P450 2D6 is mainly responsible for both deactivation of MPTP to PTP and metabolic activation of MPTP to MPP + to produce the preclinical marmoset model for Parkinson-like syndromes. In our preliminary study, we were unable to isolate P450 2D30 cDNA from marmoset livers by RT-PCR, and thus excluded P450 2D30 from further analysis. This was consisted with a reported finding that P450 2D30 was not isolated from another source of marmosets using the same P450 2D30 primer sets (Hichiya et al., 2004 ).
The present findings should provide a foundation for understanding MPTP metabolism and the successful production of preclinical marmoset Parkinsonism models. Although some differences were seen in this study in terms of major roles of drug-metabolizing enzymes involved in the MPTP activation and deactivation pathways in humans and marmosets, marmosets would be again recognized to be good preclinical model for
Parkinson's disease as reported (Ando et al., 2014; Ando et al., 2012) . A variety of genetic This article has not been copyedited and formatted. The final version may differ from this version. (Kiyotani et al., 2010) . Recently, genetic polymorphisms of P450 2D enzymes in cynomolgus and rhesus macaques were also demonstrated. In the present study, the inter-individual variations for MPTP oxidations in marmoset liver microsomes (Fig. 3) were not as high as expected, presumably because no genetic variations for marmoset P450 2D6 were confirmed in our preliminary study using the present 11 marmosets. Further study will be of interest to find more efficient individual marmosets, i.e., rapid metabolizers of P450 2D6 substrates, to effectively produce the Parkinson-preclinical animal model. 
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Fig. 2. Representative HPLC chromatograms of MPTP oxidized by marmoset liver microsomes (A,B) and recombinant FMO3 (C) and P450 2D6 (D). MPTP and its
metabolites were analyzed with a reverse-phase LC system using fluorescence and ultraviolet detection as described in Section 2.5. 
